AtriCure (ATRC) CLO receives stock awards and surrenders shares for taxes

Rhea-AI Filing Summary

AtriCure, Inc.’s Chief Legal Officer, Karl S. Dahlquist, reported equity compensation and related tax withholding transactions in company common stock. He acquired 27,991 shares through a restricted stock award and 15,198 shares through the vesting of a performance share award under the 2023 Stock Incentive Plan.

According to the filing, one third of the restricted stock will vest on each of the first, second, and third anniversaries of the grant date. The performance share award vested after company performance goals and service requirements were met.

Dahlquist also disposed of 15,687 shares at a price of $31.26 per share by transferring them back to the company to satisfy tax withholding obligations arising from the vesting and release of earlier restricted stock or performance share awards.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Dahlquist Karl S.

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,991	$0.00	--
Grant/Award	Common Stock	15,198	$0.00	--
Tax Withholding	Common Stock	15,687	$31.26	$490K

Holdings After Transaction: Common Stock — 96,542 shares (Direct)

Footnotes (1)

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahlquist Karl S.

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		27,991	A	$0(1)	96,542	D
Common Stock	03/01/2026		A		15,198	A	$0(2)	111,740	D
Common Stock	03/01/2026		F		15,687(3)	D	$31.26	96,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

2. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

3. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

Remarks:

	/s/ Karl S. Dahlquist	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AtriCure (ATRC) report for Karl S. Dahlquist?

Karl S. Dahlquist reported equity awards and related tax withholding in AtriCure stock. He acquired 27,991 restricted shares and 15,198 performance-based shares, then transferred 15,687 shares back to the company to cover tax obligations tied to prior restricted or performance share vesting.

How many AtriCure (ATRC) shares did Karl S. Dahlquist acquire in these Form 4 transactions?

He acquired 27,991 shares via a restricted stock award and 15,198 shares from a performance share award. Both awards were granted under the AtriCure, Inc. 2023 Stock Incentive Plan and reflect a mix of time-based vesting and prior achievement of company performance goals and service requirements.

What is the vesting schedule for Karl S. Dahlquist’s new restricted stock in AtriCure (ATRC)?

The restricted stock vests in three equal annual installments. One third of the 27,991 restricted shares will vest on each of the first, second, and third anniversaries of the grant date, as provided under the AtriCure, Inc. 2023 Stock Incentive Plan’s award terms.

Why did Karl S. Dahlquist dispose of AtriCure (ATRC) shares at $31.26 per share?

He transferred 15,687 shares back to AtriCure at $31.26 per share to satisfy tax withholding obligations. Those obligations arose when previously granted restricted stock or performance share awards vested and were released, and this disposition was structured as a tax-withholding transaction.

What is the nature of the performance share award reported by AtriCure (ATRC) for Karl S. Dahlquist?

The performance share award vested after AtriCure met specified company performance goals and a required service period. Upon vesting and release, Dahlquist acquired 15,198 shares of common stock under the AtriCure, Inc. 2023 Stock Incentive Plan, reflecting both performance and tenure conditions.

Are Karl S. Dahlquist’s AtriCure (ATRC) Form 4 transactions open-market buys or sales?

The filing shows equity compensation and tax withholding, not open-market trading. The acquisitions are grants and vesting of restricted and performance shares, while the disposition reflects shares transferred back to AtriCure to cover tax liabilities from those equity awards.